The phase Ib-II PANACEA study investigated the efficacy and safety of pembrolizumab plus trastuzumab in advanced HER2-positive breast cancer resistant to previous multiple lines of trastuzumab-containing therapies (60). The gene discussed is ERBB2; the disease is breast carcinoma.